iSpecimen Inc (ISPC)vsWaters Corporation (WAT)
ISPC
iSpecimen Inc
$3.00
-2.28%
HEALTHCARE · Cap: $4.34M
WAT
Waters Corporation
$365.36
-2.95%
HEALTHCARE · Cap: $34.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 366838% more annual revenue ($3.77B vs $1.03M). WAT leads profitability with a 11.9% profit margin vs 0.0%. WAT earns a higher WallStSmart Score of 50/100 (C-).
ISPC
Avoid15
out of 100
Grade: F
WAT
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+60.8%
Fair Value
$0.79
Current Price
$3.00
$2.21 discount
Margin of Safety
-84.6%
Fair Value
$178.29
Current Price
$365.36
$187.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 91.4% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Trading at 8.5x book value
ROE of 2.9% — below average capital efficiency
Operating margin of 2.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ISPC
The strongest argument for ISPC centers on Price/Book.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 91.4% demonstrates continued momentum.
Bear Case : ISPC
The primary concerns for ISPC are EPS Growth, Market Cap, Profit Margin.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Price/Book, Return on Equity. A P/E of 45.2x leaves little room for execution misses.
Key Dynamics to Monitor
ISPC profiles as a value stock while WAT is a growth play — different risk/reward profiles.
ISPC carries more volatility with a beta of 1.62 — expect wider price swings.
WAT is growing revenue faster at 91.4% — sustainability is the question.
ISPC generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
WAT scores higher overall (50/100 vs 15/100) and 91.4% revenue growth. ISPC offers better value entry with a 60.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
iSpecimen Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
iSpecimen, Inc. provides technology that connects life science researchers in need of human biofluids, tissues and living cells for their research with biospecimens available from healthcare provider organizations globally. The company is headquartered in Lexington, Massachusetts.
Visit Website →Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?